Allos Therapeutics Reports 2011 Financial Highlights And Key Business Priorities
Allos expects that license and other revenue and cost of license and other revenue for the fourth quarter of 2011, related to the agreement with Mundipharma International Corporation Limited, will approximate $1.0 million and $0.5 million, respectively. This guidance relates to expected research and development and regulatory services to be performed by the Company, and includes Mundipharma’s current 40% share of jointly agreed-upon clinical development expenses for FOLOTYN.
As of December 31, 2011, the Company had $97.8 million in total cash, cash equivalents and investments. The Company expects its cash position will be sufficient to fund operations through at least early 2015. This projection is based on certain assumptions for modeling purposes only (and in the case of future revenue levels, should not be considered the Company’s financial guidance), including: (i) future net product sales levels and cost of sales remaining consistent with our actual results for fiscal year 2011, and (ii) our annual cash-based operating expenditures, excluding cost of sales, non-cash stock-based compensation and depreciation expense and net of expected reimbursements from Mundipharma for jointly funded clinical trials, approximating $72 to $75 million per year for 2012 through 2015.
Growth in U.S. sales and/or potential milestone payments and royalties associated with regulatory approval of FOLOTYN in the European Union have the potential to further extend our cash resources assuming our costs remain consistent with our projections.
Non-GAAP financial information is utilized by Allos' management to provide a useful measure of operating performance of the company. Non-GAAP financial information herein includes the financial guidance related to projected operating expenditures. We report the expected reimbursements from Mundipharma as License and Other Revenue in accordance with generally accepted accounting principles but have netted such reimbursements against operating expenditures for purposes of presentation herein. In addition, guidance for operating costs and expenses excludes cost of sales, cost of license and other revenue, amortization of intangible asset and non-cash stock based compensation expense, which is not being provided at this time.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts